GSK3 Inhibitors and Disease

被引：43

作者：

Hernandez, Felix ^{[1
]}

Diaz Nido, Javier ^{[1
]}

Avila, Jesus ^{[1
,2
,3
]}

Villanueva, Nieves ^{[4
]}

机构：

[1] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain

[2] CIBERNED, Madrid, Spain

[3] Serv Neurol, Madrid, Spain

[4] Inst Salud Carlos III, Madrid, Spain

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2009年 / 9卷 / 09期

关键词：

GSK3; lithium; Alzheimer; neurodegeneration; GLYCOGEN-SYNTHASE KINASE-3; DEPENDENT PROTEIN-KINASE; PAIRED HELICAL FILAMENTS; BLOOD-BRAIN-BARRIER; SPINAL-CORD-INJURY; VIRUS P-PROTEIN; TAU-PROTEIN; ALZHEIMERS-DISEASE; POTENT INHIBITORS; THERAPEUTIC TARGET;

D O I：

10.2174/138955709788922647

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

This review describes, briefly, the characteristics and regulation of glycogen synthase kinase 3 (GSK3) together with the role of GSK3 dysfunctions in different pathologies, and GSK3 as target for therapeutic treatment in different diseases. Several GSK3 inhibitors acting at different levels are described in this work, ranging from cations like lithium to small compounds developed by different pharmaceutical companies. Also, the use of specific interference RNA (iRNA) for the specific inhibition of the expression of the different GSK3 isoforms is discussed.

引用

页码：1024 / 1029

页数：6

共 80 条

[1] Axin-mediated CKI phosphorylation of β-catenin at Ser 45:: a molecular switch for the Wnt pathway [J].

Amit, S ;

Hatzubai, A ;

Birman, Y ;

Andersen, JS ;

Ben-Shushan, E ;

Mann, M ;

Ben-Neriah, Y ;

Alkalay, I .

GENES & DEVELOPMENT, 2002, 16 (09) :1066-1076

[2] Phosphorylation of human respiratory syncytial virus P protein at serine 54 regulates viral uncoating [J].

Asenjo, Ana ;

Gonzalez-Armas, Juan C. ;

Villanueva, Nieves .

VIROLOGY, 2008, 380 (01) :26-33

[3] Residues in human respiratory syncytial virus P protein that are essential for its activity on RNA viral synthesis [J].

Asenjo, Ana ;

Mendieta, Jesus ;

Gomez-Puertas, Paulino ;

Villanueva, Nieves .

VIRUS RESEARCH, 2008, 132 (1-2) :160-173

[4] Role of tau protein in both physiological and pathological conditions [J].

Avila, J ;

Lucas, JJ ;

Pérez, M ;

Hernández, F .

PHYSIOLOGICAL REVIEWS, 2004, 84 (02) :361-384

[5]

Beaulieu JM, 2008, CELL, V132, P125, DOI 10.1016/j.cell.2007.11.041

[6] Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418 [J].

Bhat, R ;

Xue, YF ;

Berg, S ;

Hellberg, S ;

Ormö, M ;

Nilsson, Y ;

Radesäter, AC ;

Jerning, E ;

Markgren, PO ;

Borgegård, T ;

Nylöf, M ;

Giménez-Cassina, A ;

Hernández, F ;

Lucas, JJ ;

Díaz-Nido, J ;

Avila, J .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (46) :45937-45945

[7] Glycogen synthase kinase 3: a drug target for CNS therapies [J].

Bhat, RV ;

Haeberlein, SLB ;

Avila, J .

JOURNAL OF NEUROCHEMISTRY, 2004, 89 (06) :1313-1317

[8] Wnt signaling: complexity at the surface [J].

Cadigan, KM ;

Liu, YI .

JOURNAL OF CELL SCIENCE, 2006, 119 (03) :395-402

[9] Tau therapeutic strategies for the treatment of Alzheimer's disease [J].

Churcher, Ian .

CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (06) :579-595

[10] INHIBITION OF GLYCOGEN-SYNTHASE KINASE-3 BY INSULIN-MEDIATED BY PROTEIN-KINASE-B [J].

CROSS, DAE ;

ALESSI, DR ;

COHEN, P ;

ANDJELKOVICH, M ;

HEMMINGS, BA .

NATURE, 1995, 378 (6559) :785-789

← 1 2 3 4 5 6 7 8 →